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Abstract
Background: The worldwide experience of surgical resection for isolated metastasis following liver transplantation
(LT) for hepatocellular carcinoma (HCC) is limited.
Methods: The case of a 60-year-old patient performed successful surgical management for metachronous
pulmonary and adrenal metastases from HCC after LT.
Results: Eighty months after LT, he was presently alive and disease-free with a normal AFP value.
Conclusion: The case is an interesting report on a somehow indolent metastatic spread of HCC after LT. It should
be considered that metachronous metastatic resectable disease, with no data of recurrence at the primary site in
an operable patient, is an indication to perform a surgical resection.
Keywords: liver transplantation, metachronous, metastasis, surgical management
Background
The worldwide experience of surgical resection for iso-
lated metastasis following liver transplantation (LT) for
hepatocellular carcinoma (HCC) is limited [1-3]. Here
we reported a rare case of successful surgical manage-
ment of metachronous pulmonary and adrenal metas-
tases after LT for HCC. To our knowledge, successful
managements for metachronous pulmonary and adrenal
metastases from HCC after LT have not been previously
reported in English literature.
Case presentation
A 60-year-old man, with a 20-year history of type B
hepatitis and hepatic cirrhosis, presented with a solid
large mass in the left lateral segment. The patient was
poor-hepatic functional reserve because of atrophy of
the right liver and compensative hyperplasia of the left
liver according to imaging studies. The serum alpha-
fetoprotein (AFP) value was 7,812.0 ng/ml, serum albu-
min level was 29.4 g/L, and other laboratory data were
within normal limits. The Child-Pugh classification of
the cirrhosis was Child early B cirrhosis. He underwent
LT on 9 February 2004 and had received 3 cycles’
postoperative adjuvant chemotherapy with capecitabine
and oxaliplatin for 5 months. After LT, the AFP value
decreased within a normal range and stayed normal for
thirty months.
Thirty-three months after LT, a 3.0 cm×3.5 cm lesion
was detected in the right lung with elevated AFP value
(167.1 ng/ml). Because positron emission tomography
(PET) scan revealed no fluorodeoxyglucose (FDG)-avid
focus in transplanted liver and other extrahepatic
organs, partial resection of the lower lobe of the right
lung was performed. After pulmonary resection, the
AFP value decreased within a normal range.
Thirty-nine months after LT, an abdominal computed
tomography (CT) scan revealed a 4.0 cm×3.5 cm homo-
geneous mass in the left adrenal gland with elevated
AFP value (55.8 ng/ml) (Figure 1A). Furthermore, the
PET scan revealed a FDG-avid enlarged left adrenal
gland without FDG-avid activity in transplanted liver.
Neither recurrent nor metastatic foci in any other
organs was detectable after thorough examination,
except for the left adrenal grand. Review of the older
PET scan and other imaging studies showed no evidence
of the adrenal lesion. The American Society of Anesthe-
siologists (ASA) grade of the patient was II grade. Based
on the previous findings, a laparoscopic extraperitoneal
adrenalectomy was performed on 13 May 2007.
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Postoperatively, the patient received 6 cycles’ adjuvant
chemotherapy with gemcitabine and 5-fuorouracil.
Three years after adrenalectomy, the patient is presently
alive and disease-free with a normal AFP value. He is
presently on tacrolimus and sirolimus for immunosup-
pression. The tumor metastases and therapeutic inter-
ventions related with the changes of the AFP levels
could be seen in Figure 2.
Histopathology
The histopathology of the resected liver revealed a large
tumor in the left lobe (9 cm×8 cm×8 cm) with features
of poorly differentiated hepatocellular carcinoma. The
uninvolved liver showed cirrhosis (Figure 1B). The
tumors in the lung and adrenal were 3.0 cm×3.0 cm×
3.5 cm and 3.0 cm×3.3 cm× 4.0 cm in size, respectively.
The histological findings of the lung tumor showed that
cells with round nuclei proliferated in clusters, and
mitoses were visible in many nuclei (Figure 1C). In the
adrenal gland, well-defined oval cells or nuclei prolifer-
ated solidly, and necrotic tissue was visible in the can-
cerous lesion (Figure 1D). AFP-positive cells were
identified by immunohistochemistry both in the lung
and adrenal lesions.
Discussion
LT is claimed to cure HCC and the underlying cirrhosis
simultaneously in selected patients. Nevertheless, a care-
ful follow-up is needed in those cases due to the possi-
bility of neoplastic recurrence, which could take place
not only in the graft, but also in extrahepatic organs
such as lung, adrenal glands, and bone [4]. The cumula-
tive survival rates of 6, 12, 24, and 36 months after the
initial diagnosis of extrahepatic metastases were 44.1%,
21.7%, 14.2%, 7.1%, respectively. The median survival
time was 4.9 months (range, 0-37 months) [5]. Extrahe-
patic metastasis is a common cause of deaths in patients
after LT. Those patients, who usually have multiple
Figure 1 Enhanced abdominal computed tomography. A, Enhanced abdominal computed tomography revealed a homogeneous 4.0 cm×3.5
cm mass in the left adrenal gland with no calcification. B, The histological findings of the hepatic tumor. C, The histological findings of the lung
tumor.D, The histological findings of the adrenal tumor (H&E, Stain×400).
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metastases, could only be offered supportive care or pal-
liative chemotherapy. However, previous studies showed
that a solitary metastasis might have the opportunity of
surgical resection [1,6,7]. In a report from Lyon, there
were 7 patients who underwent adrenalectomy for meta-
static HCC, two died in the postoperative period in rela-
tion with pulmonary embolism (n = 1) or acute
pancreatitis (n = 1), and the mean survival time of the
other five patients were 38 months after adrenalectomy
[8].
The worldwide experience of surgical resection for
isolated metastasis following LT for HCC is limited to
case reports [1-3]. Rubio E et al reported one patient
underwent adrenalectomy for the right adrenal metasta-
sis 3 years after LT for HCC. The patient was alive
when reported and disease-free for 24 months after
adrenalectomy [1]. Herein, we have described a rare
case of successful surgery for metachronous pulmonary
and adrenal metastases after LT for HCC. Our patient
had a unique character of metachronous metastasis
instead of the systemic spread of cancer after operation.
There were two metastatic sites: the lung and the adre-
nal gland; but each metastatic lesion was detectable only
as a metachronous focus without any evidence of local
recurrence or other extrahepatic metastasis. Further-
more, the patient’s AFP level was closely corelated to
tumor metastasis, which was a good indicator for tumor
metastasis and made the surgical approach possible [9].
Palliative chemotherapy could be delivered to patients
with recurrent HCC after LT with tolerable toxicity
[10]. Capecitabine plus oxaliplatin regimen showed
modest anti-tumour activity with tolerable toxicities in
patients with advanced HCC [11,12]. Therefore, Capeci-
tabine plus oxaliplatin regimen were followed routinely
in patients with large and poorly differentiated hepato-
cellular carcinoma after LT in our centre. The patient is
Figure 2 The patient’s AFP level. The patient’s AFP level was closely correlated to tumor metastases and therapeutic interventions.
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presently alive and disease-free for three years after the
third operation. We hypothesize some potential benefi-
cial elements, such as complete surgical removal, unu-
sual sensitivity to adjuvant therapy [13], endocrine
influence [14], allergic reaction [15], and interference
with nutrition of the tumor [16]. We believe severe fol-
low up is necessary for the patient in future.
Conclusion
In conclusion, this is an interesting report on a some-
how indolent metastatic spread of HCC. It should be
considered that metachronous metastatic resectable dis-
ease, with no data of recurrence at the primary site in
an operable patient, is an indication to perform a surgi-
cal resection.
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